- Non-small cell lung cancer often becomes a chronic disease due to precise medicine and personalized treatment2020 | Publication without faculty affiliation
- Nonsmall cell lung cancer with RET gene fusion2021 | Publication without faculty affiliation
- Non-small-cell lung cancer - koncertant diagnostic and therapeutic news2016 | Faculty of Medicine in Pilsen
- Strategy of treatment of metastatic non-small-cell lung cancer - squamous cell carcinoma2016 | First Faculty of Medicine
- Non-small cell lung cancer with ALK and R0S1 genes rearregement2018 | Faculty of Medicine in Pilsen
- Nemalobuněčný karcinom plic ROS1 pozitivní, léčený crizotinibem - kazuistika2018 | Second Faculty of Medicine
- Nemalobuněčný karcinom plic s přestavbou genu ALK a ROS1, léčený lorlatinibem2019 | Second Faculty of Medicine
- New treatment options - Non small cell lung cancer with rebuilding EML 4-ALK gene2014 | Faculty of Medicine in Pilsen
- ALK-driven non-small cell lung cancer: Prevention, prophylaxis, and treatment of brain metastases2021 | Faculty of Medicine in Pilsen
- Strategie léčby metastatického onemocnění - skvamózní nemalobuněčné karcinomy plic2016 | First Faculty of Medicine
- Nemalobuněčný karcinom plic - vzácný nežádoucí účinek léčby nivolumabem2022 | First Faculty of Medicine
- Nivolumab-Induced Psoriasis in a Patient with Lung Cancer. Case Report2022 | Faculty of Medicine in Hradec Králové
- Therapy of metastatic non-squamous lung cancer with bevacizumab plus pemetrexed2016 | Faculty of Medicine in Pilsen
- Treatment of lung cancer with targetable mutations - new drugs and indications2023 | First Faculty of Medicine
- Targeted treatment and immunotherapy of advanced non-small cell lung cancer2022 | First Faculty of Medicine
- Present and new trends in the treatment of non-small cell lung cancer2016 | Publication without faculty affiliation
- ALK-positive advanced non-small cell lung cancer patient with poor performance status - case report2023 | Third Faculty of Medicine
- Léčba nemalobuněčného karcinomu plic Xalkori2017 | Publication without faculty affiliation
- Imunoterapie v první linii léčby metastatického nemalobuněčného plicního karcinomu2019 | Second Faculty of Medicine
- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- Lorlatinib in the treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Atypical response to anti-PD-1 therapy followed by long-term survival in non-small cell lung cancer - case reports2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib2016 | Faculty of Medicine in Pilsen
- Testování exprese PD-L1 u nemalobuněčného karcinomu plic2017 | First Faculty of Medicine
- Monoclonal antibodies in the treatment of non-small cell lung carcinoma2017 | Publication without faculty affiliation
- Immunotherapy in the first line treatment of non-small cell lung cancer2020 | Faculty of Medicine in Pilsen
- What else after the failure of the first line EFGR-TKI treatment2015 | Faculty of Medicine in Pilsen
- Co nového v imunoterapii na WCLC 20192019 | Second Faculty of Medicine
- Atezolizumab in the first line of treatment for non-squamous metastatic non-small cell lung cancer2019 | Second Faculty of Medicine